Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Nephrotic Syndrome, Hyperlipidemia
In brief
OBJECTIVES: I. Determine the effect of atorvastatin on the plasma levels of lipids, Lp(a), and apoproteins for treating hyperlipidemia in children with nephrotic syndrome in whom proteinuria and hyperlipidemia persist after other appropriate measures to treat their primary disease have been exhausted. II. Determine the safety and tolerability of atorvastatin in these patients. III. Provide preliminary data for a future investigation into the potential effect that lowering cholesterol levels may have on the rate of progression of renal insufficiency in such patients.
Key facts
- Study ID
- NCT00004466
- Run by
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- People needed
- 5
- Starts
- 1998-10-01
- Expected to finish
- 1999-12-01
- Last updated by the study team
- 2017-09-15
Who can join
Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Medical City Dallas Hospital — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.